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Introduction. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a debilitating disorder of unknown aetiology,
characterised by severe disabling fatigue in the absence of alternative diagnosis. Historically, there has been a tendency to draw
psychological explanations for the origin of fatigue; however, this model is at odds with findings that fatigue and accompanying
symptoms may be explained by central and peripheral pathophysiological mechanisms, including effects of the immune, oxidative,
mitochondrial, and neuronal pathways. For example, patient descriptions of their fatigue regularly cite difficulty in maintaining
muscle activity due to perceived lack of energy. This narrative review examined the literature for evidence of biochemical
dysfunction in CFS/ME at the skeletal muscle level.Methods. Literature was examined following searches of PUBMED,MEDLINE,
and Google Scholar, using key words such as CFS/ME, immune, autoimmune, mitochondria, muscle, and acidosis. Results.
Studies show evidence for skeletal muscle biochemical abnormality in CFS/ME patients, particularly in relation to bioenergetic
dysfunction. Discussion. Bioenergetic muscle dysfunction is evident in CFS/ME, with a tendency towards an overutilisation of the
lactate dehydrogenase pathway following low-level exercise, in addition to slowed acid clearance after exercise. Potentially, these
abnormalities may lead to the perception of severe fatigue in CFS/ME.
1. Introduction
Chronic fatigue syndrome (CFS) also known as Myalgic
Encephalomyelitis (ME) is a heterogeneous disorder of
unknown aetiology [1]. The condition is characterised by
severe disabling fatigue in the absence of alternative diagnosis
and is associated with a myriad of other symptoms, including
but not limited to postexertional malaise, sleep disturbance,
and cognitive dysfunction [1–6]. The prevalence of CFS/ME
in the adult population is estimated at around 0.2%–2.6%
worldwide [5, 7–9]. For example, the Centre for Disease
Control 1994 criteria (CDC4) [10] and the Canadian criteria
[11] provide a strict definition and estimate prevalence to
be lower (0.2%) than previously reported in a primary care
setting whereby a less stringent criteria was applied [5].
In the UK, the condition affects approximately 600,000
individuals, with a peak incidence in the 20–40 age group and
a preponderance in females, at a ratio of 6 : 1 [8, 12].
It is important to note that recently there has been intense
interest surrounding the naming of the condition. Early in
2015 the Institute of Medicine (IOM) [13] issued a report that
proposed a new case definition for CFS/ME, recommending
the renaming the illness as Systemic Exertion Intolerance
Disease (SEID). This new case definition requires a substan-
tial reduction in ability to complete preillness activities, unre-
freshing sleep, postexertional malaise, and either cognitive or
orthostatic intolerance. In a recent study conducted by Jason
et al. [14], the new SEID criteria were reported to identify a
group of patients comparable in size to the Fukuda criteria
but a larger group than the Canadian criteria. Additionally,
the name was reported to select more patients who had
less impairment and fewer symptoms than four-item empiric
criteria. Presently, there is considerable debate among scien-
tists as regards which case definition to use for clinical and
research purposes. As indicated in the IOM report [13]
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funding was limited so an inadequate number of studies have
focused on the validity and reliability of the case definition
[14]. Thus, further research utilising empirical methods is
required to fully evaluate the criteria and develop a consensus
among researchers, clinicians, and the patient community
[14].
One of the primary symptoms of CFS/ME is generalised
abnormal muscle fatigue that occurs after relatively mild
activity [3, 10, 15]. Fatigue can be defined as a progressive
impairment in maximal force generating capacity that devel-
ops during muscular activity [16].
Historically, there has been a tendency to draw psycho-
logical explanations for the origin of fatigue in CFS/ME;
however this model is at odds with patient perceptions of the
nature of their condition, with many suggesting a “periph-
eral” as opposed to “central” origin [15]. For example, patient
descriptions of their fatigue regularly cite difficulty in main-
taining muscle activity due to perceived lack of energy or
through muscle pain, which can be serious enough to lead to
the avoidance of exercise [17].
In terms of the pathophysiological basis of peripheral
muscle fatigue in CFS/ME, a wide range of potential mecha-
nisms have been suggested. Recent studies [2, 15] using novel
magnetic resonance spectroscopy (MRS) techniques have
reported distinctive and reproducible muscle bioenergetic
abnormality in patients following repeat exercise, contrasting
previous work that has reported an absence in increased
glycolytic metabolism and lactic acid production in the
majority of CFS/ME study participants [18–20]. Additionally,
the role of enhanced oxidative stress in CFS/ME has also
been reported as a potential mechanism in muscle fatigue,
with CFS/ME exhibiting elevated blood oxidative status at
rest [21, 22] which is accentuated during exercise [22]. Fur-
thermore, there is evidence to suggest a role of mitochondrial
dysfunction in CFS/ME, illustrated by lowered ATP produc-
tion, impaired oxidative phosphorylation, andmitochondrial
damage [23, 24]. Moreover, a key symptom associated with
CFS/ME is postexertional malaise (PEM), following physical
or emotional stress [25]. Studies have reported exercise in
CFS/ME patients to exhibit the potential to amplify preexist-
ing immune dysfunction. Finally, a recent study [26] reported
abnormality in AMP-activated protein kinase (AMPK) acti-
vation and glucose uptake, when CFS/ME patient skeletal
muscle function was assessed via a novel in vitro technique.
Evidence exists to suggest that a wide range of biochemi-
cal abnormalities exist at the skeletal muscle level in CFS/ME.
This narrative review will explore current evidence regarding
the various proposed mechanisms underlying peripheral
muscle dysfunction in CFS/ME, which are outlined in
Table 1. Ultimately, to gain an improved understanding of
muscle dysfunction and the end point of severe disabling
fatigue associated with this debilitating condition, improved
understanding of the aetiology underlying CFS/ME is pivotal
within the field of ageing research, with CFS/ME recognised
as an ageing related condition, with symptoms perpetuated
amongst older patients.
In terms of methodology, this narrative review examines
literature following searches of the electronic databases: PUB
MED, MEDLINE, and Google scholar. All papers published
up until August 2015 were eligible for inclusion in this
review. The search included the following terms: CFS, ME,
Immune, autoimmune, mitochondria, muscle, oxidative and
nitrosative stress, acidosis, bioenergetics, and AMPK. A total
of 435 papers were defined by search, with a total of 67 papers
included in this review.
2. Central Sensitisation
Central sensitisation is defined as an alteration in the respon-
siveness of central neurons to input from unimodal and poly-
modal receptors [44]. Central sensitisation involves a number
of top-down and bottom-up mechanisms, which contribute
to the hyperresponsiveness of the central nervous system to a
variety of stimuli [28]. It is important to note that an alteration
in central pathways may impact upon peripheral muscle
fatigue.
In terms of central impairment, the perception of fatigue
during exercise is not always abnormal and serves an impor-
tant function during significant physical exertion [2]. For
example, in a study conducted by Amann and Dempsey [45]
peripheral muscle fatigue was induced in patients and conse-
quently fatiguing muscle was reported to play a pivotal role
in the determination of central motor drive and force output.
Therefore, suggesting the presence of a feedback signal from
peripheral muscle to the central nervous system, to ensure
fatigue, is confined to a certain level, preventing damage to
the individual. However, it is plausible that peripheral fatigue
experienced in CFS/ME is the direct result of excessive signal
feedback, leading to a disproportionate perception of fatigue
early in the fatiguing process associated with physical activity
[15].
Interestingly, evidence exists to suggest the role of central
impairment in CFS/ME patients. For example,Whiteside and
colleagues [25] reported CFS/ME patients to exhibit a dys-
function of nociceptive inhibition during exercise. This was
demonstrated by a decrease in pain threshold following exer-
cise, which is abnormal as pain threshold normally increases
during exercise due to a greater release of endogenous opioids
and additional inhibitory mechanisms (descending inhibi-
tion). This exercise-induced abnormality was also reported
in two additional studies [17, 27]. For example, Meeus and
colleagues [27] comparedCFS/MEpatients with chronic pain
(𝑛 = 26), healthy control participants (𝑛 = 31), and chronic
back pain patients (𝑛 = 21). Participants all completed a
submaximal aerobic exercise protocol, which was followed by
venous blood sampling (nitric oxide) and algometry (hand,
arm, calf, and lower back). Results demonstrated patients
with CFS/ME to exhibit lower pain threshold compared to
both the healthy control participants and chronic lower back
pain participants. Taken together the results demonstrate
CFS/ME patients to have a lack of descending inhibition
during exercise. The implication of a lack of endogenous
inhibition has been suggested to account in part for the PEM
experienced by CFS/ME patients.
Evidence also exists to suggest a role of generalised
hyperalgesia in CFS/ME as outlined by Nijs and colleagues
[28]. It has been suggested that lower pain thresholds in
symptomatic locations represents primary hyperalgesia due
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Table 1: Summary of various proposed mechanisms underlying muscle dysfunction in CFS/ME.
Proposed mechanism underlying muscle dysfunction in CFS/ME Study
Central sensitisation
Decreased pain threshold in patients. Whiteside et al. (2004) [25],Meeus et al. (2010) [27]
Generalised hyperalgesia. Nijs et al. (2012) [28], Vecchiet etal. (2003) [29]
Oxidative and nitrosative stress
Elevated TBARS prior to exercise in patients with history of severe infection. Jammes et al. (2013) [22]
Elevated TBARS in patients with history of stress factors. Jammes et al. (2012) [30]
Oxidative damage to endogenous epitopes, autoimmunity, and links with muscle fatigue. Maes et al. (2006) [31]
Mitochondrial dysfunction
Mitochondrial function influenced by increased immune-inflammatory stress pathways in patients. Broderick et al. (2010) [32]
Reduction inTh1 andTh17 function and movement towardTh2 dominant immunity. Brenu et al. (2011) [33]
Reduction in mitochondrial enzyme level citrate synthase in patient muscle samples. Skowera et al. (2004) [34]
Reduction in mitochondrial enzymes succinate reductase and cytochrome-C oxidase in skeletal muscle
of patients. McArdle et al. (1996) [35]
No difference in cytochrome-C oxidase levels in muscle biopsies. Edwards et al. (1993) [36]
Patients reported to exhibit reduced levels of coenzyme Q10, with a significant inverse relationship
between plasma coenzyme Q10 and fatigue severity measured via fibro fatigue scale. Maes et al. (2009) [37]
Postexertional malaise (PEM) and immune function
Moderate intensity exercise and symptom flare (PEM) in patients, directly linked to IL-𝛽, IL-12, IL-8,
IL-10, and IL-13. Increased TNF-𝛼 postexercise in patient cohort postexercise. White et al. (2004) [38]
Moderate intensity exercise also reported to induce a larger 48-hour postexercise area under the curve
for IL-10 in patients. Light et al. (2012) [39]
In comparison of 23 case control studies no evidence of a significant change in circulating
pro/anti-inflammatory cytokines was reported. However, exaggerated complement system response,
indicated by C4C split product level, enhanced oxidative stress and combined delayed and reduced
antioxidant response.
Nijs et al. (2014) [40]
Muscle bioenergetic dysfunction
Evidence of significant (𝑃 < 0.05) suppression in proton efflux immediately after exercise and
significantly prolonged time to reach maximum proton efflux following low-level exercise (plantar
flexion, 35% MVC).
Jones et al. (2010) [15]
Prolonged postexercise recovery from exercise in patients, indicated by marked increase in
intramuscular acidosis compared to controls at a similar work rate. After each 3-minute bout of
exercise (plantar flexion, 35% MVC), a 4-fold increase in the time taken to recover to baseline.
Jones et al. (2012) [2, 41]
No difference in intramuscular pH at rest, exhaustion, and early or late recovery following graded
exercise to exhaustion. However, evidence of accelerated glycolysis at onset of exercise was illustrated
by more rapid PCr depletion.
Wong et al. (1992) [42]
No consistent abnormalities in pH regulation following exercise when patient cohort is taken as a
whole. However, 6 patients exhibited increased intramuscular acidification in relation to PCr depletion. Barnes et al. (1993) [18]
In subanaerobic threshold exercise protocol only small subgroup of patients reported to have increased
blood lactate responses to exercise. Lane et al. (1998) [20, 43]
Abnormal AMPK activation and glucose uptake
No increase in AMPK phosphorylation or glucose uptake 16 hours following electrical pulse stimulation
in CFS/ME patients. Compared to significant increases in both parameters in control participants. Brown et al. (2015) [26]
to sensitised nociceptors within injured peripheral muscle
tissue. However, the authors also commented that when pain
thresholds are detected in asymptomatic areas, then central
sensitisation is at play. Two studies conducted byVecchiet and
colleagues [29] investigated the effect of electrical stimulation
of muscle tissue, skin, and subcutis in relation to pain thresh-
old in CFS/ME patients and healthy control participants.
Interestingly, in both studies CFS/ME participants reported
there to be no significant difference between groups for
electrical pain threshold of skin and subcutis. Nevertheless, a
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much lower electrical pain threshold was observed in all sites
of muscle tissue (trapezius, quadriceps, and deltoid) for the
CFS/ME group only, illustrative of hyperalgesia in CFS/ME.
3. Oxidative and Nitrosative Stress
Enhanced oxidative and nitrosative stress has been reported
in CFS/ME patients. For example, studies have demonstrated
patients to exhibit excessive production of reactive oxygen
species (ROS) following physical exertion, as well as altered
resting blood oxidant to antioxidant status [21, 22].
Biochemical markers associated with oxidative stress
have also been reported to play a pivotal role in skeletal mus-
cle fatigue [46], which is often cited as a debilitating symptom
experienced by CFS/ME patients [22]. Effectively, oxidative
and nitrosative stress involve the enhanced production of
ROS and reactive nitrogen species (RNS), in addition to
other free radicals; these reactive species have the potential to
disrupt cell membrane function through lipid peroxidation,
as well as damage to functional proteins and DNA. This can
ultimately lead to alterations in cell structure and disease
initiating mutations [47].
Elevated ROS/RNS exhibit the capacity to profoundly
impair mitochondrial function, which has been suggested
to be due to the accumulation of oxidative modified mito-
chondrial proteins, lipids, and DNA [48]. Moreover, these
factors exhibit the potential to induce electron transport
chain dysfunction, impairment in cellular bioenergetics,
and ultimately skeletal muscle fatigue. Furthermore, skeletal
muscle is a postmitotic tissue so it is extremely susceptible
to mitochondrial oxidative damage; this is due to being ter-
minally differentiated and because of a slow cellular turnover
and high metabolic rate [48].
Mitochondria are a major source of ROS and RNS gener-
ation in cells and are therefore highly susceptible to oxidative
damage. For example, they exhibit reduced levels of antiox-
idants such as glutathione in comparison to levels found
in the cytosol [49]. This relative lack of protection enables
mitochondrial DNA (mtDNA) to be damaged, leading to
major changes in polypeptide synthesis. Finally, mtDNA
repair enzyme activity is considerably lower than found in the
nucleus [50].The combined effects lead to a reduced electron
transfer rate with subsequent reduction in the rate of ATP
synthesis [51].
In relation to the impact of elevated oxidative stress on
muscle dysfunction,muscle specific symptomsof fatigue have
been reported to be proportional to the blood levels of a
marker of ROS induced lipid peroxidation, thiobarbituric
acid reactive substances (TBARS) [21]. TBARS occurs in the
serum due to the peroxidation of low-density lipoproteins
and oxygen mediated injury of myocyte membranes [29, 52].
Lipid peroxidation of skeletal muscle fibres induces a loss
of membrane excitability because of altered activation of K+
channels [27, 53]. Additionally, muscle biopsies from healthy
adults indicated that the intensity of membrane excitation
was proportional to K+ efflux measured in plasma [54], with
an increase in ROS generation acting to inhibit Na+-K+ pump
activity, thus reducing the K+ outflow and muscle membrane
excitability [55, 56]. Furthermore, in another study [57]
CFS/ME patients were reported to exhibit a reported a loss
of Na+/K+ and Ca2+-ATPase pump regulation, as well as
alterations in the ryanodine channels within the sarcoplasmic
reticulummembrane.This was related to increased fluidity of
the sarcoplasmic membrane due to ROS induced formation
of lipid hydroperoxides, which the authors suggested to sup-
port the hypothesis that sarcolemma conduction system with
some aspects of Ca2+ transport was negatively influenced in
CFS/ME.
Furthermore, in an additional study [22] blood oxidant
status and muscle membrane excitability were measured
before and after exercise. The case control study compared
CFS/ME patients (𝑛 = 55) and healthy matched controls
(𝑛 = 40). However, within the CFS/ME cohort two sub-
groups emerged, firstly, those who had reported severe infec-
tion (e.g., pneumonia, sepsis, encephalomyelitis, and H1N1
influenza) within 3–7 months preceding onset of CFS/ME
symptoms (infected CFS/ME group (I-CFS/ME)); secondly,
those who had practiced sport to a high level (>6 hrs per
week) for 6 years prior to the onset of CFS/ME symptoms and
with no history of severe infection (i.e., noninfected CFS/ME
[NI-CFS/ME]). Participants were required to complete a
maximal incremental cycle based protocol to reach the point
ofmaximal oxygen uptake. In relation tomarkers of oxidative
stress, blood samples were obtained before, during, and
after exercise time points, enabling plasma concentration of
TBARS and endogenous antioxidant (reduced ascorbic acid)
to be measured. Additionally, action potentials (M-wave)
were evoked in the vastus lateralis to exploremuscle excitabil-
ity.
Results demonstrated all CFS/ME patients to exhibit
abnormal biochemical and electrophysiological measures
indicated by elevated TBARS levels prior to exercise and
altered M-wave configuration during and after exercise.
These findings are in agreement with other studies
[19, 22, 58] which have also reported an elevated blood
oxidant status at rest, which was accentuated by exercise, in
addition to reduced muscle excitability. For example, one
study described enhanced exercise-induced oxidative stress
in CFS/ME patients, which was indicated by early changes in
TBARS and reduced ascorbic acid in response to incremental
exercise. Furthermore, CFS/ME patients also exhibited
marked alterations in muscle membrane excitability,
indicated by lengthened M-wave duration during the
recovery period [58].
However, a pivotal finding of the more recent study [22]
was that I-CFS/ME patients exhibited significant accentua-
tion of blood oxidant status at rest, in addition to muscle
hypoexcitability at work, as well as significantly reduced K+
outflow in response to maximal exercise. Therefore, CFS/ME
patients with a history of previous severe infection exhibited
greater biological and EMGdisorders compared to those who
reported completing a high level of physical activity before
the onset of fatigue related symptoms.The authors concluded
severe infection to act as a stressor responsible for the
alteration in blood oxidant status, which may help to explain
impaired exercise-inducedK+ outflow and alteredmembrane
excitability. However, it is important to acknowledge that
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the NI-CFS patients self-reported their physical activity level
for the 6 yrs prior to the onset of CFS/ME symptoms.
Therefore, it is possible that CFS/ME patients overestimated
their physical activity habits prior to developing CFS/ME
symptoms.
Jammes et al. [30] also measured TBARS at rest and
following exercise in a CFS/ME patient cohort. Effectively,
CFS/ME patients were separated into 4 distinct groups.These
were as follows: group I (no relevant previous history),
group II (previous high-level sport), group III (previous
severe acute infection), and group IV (high-level sport and
severe acute infection). Patients were required to complete a
maximal cycle protocol before blood samples were collected
and plasma was analysed for TBARS and heat shock proteins
HSP27 and HSP70. Interestingly, in agreement with other
studies [22] the authors reported elevated TBARS at rest in
CFS/ME patients compared to controls; however this was
only demonstrated in CFS/ME groups II, III, and IV. In
contrast to the previously described studies, the authors also
measured HSP levels at rest and reported significantly lower
levels in all CFS/ME patient groups compared to controls.
Following exercise, the peak level of TBARS was increased
in CFS/ME groups II, III, and IV. HSP27 and HSP70 were
suppressed with the greatest effect in groups III and IV.
Therefore, the authors concluded a history of previous stress
factors in a CFS/ME patient cohort to be associated with
severe and the suppression of protective HSP response to
exercise. Similarly, Thambirajah et al. [59] investigated HSP
expression at rest and following exercise in a CFS/ME patient
cohort. The authors reported basal HSP27 to be elevated in
CFS/ME patients compared to controls. Additionally, HSP27
levels decreased immediately after exercise and remained
below basal level at day 1 after exercise. In contrast, HSP27
levels were constant at basal and following exercise in the
control group. There was also an observed decline in HSP60
and HSP90 in the CFS/ME patient group at 7 days after
exercise. The findings were postulated to be evidence of an
abnormal or defective adaptive response to oxidative stress
in CFS/ME.
Moving on, excessive oxidative and nitrosative stress
has also been suggested to be associated with secondary
autoimmune responses. Prolonged oxidative and nitrosative
stress may cause damage to protein and lipid structures to
such an extent that they lose immunogenic tolerance and
autoantibodies begin to be formed against them [60]. For
example, secondary IgM and IgG mediated autoimmune
reactions have been reported to occur in patients with
CFS/ME. For example, Maes et al. [31] examined whether
CFS/ME was accompanied by a response to neoepitopes
and a variety of modified lipids and proteins indicative of
damage caused by excessive oxidative and nitrosative stress.
Specifically, the authors examined serum antibodies to fatty
acids (oleic, palmitic, and myristic acid), by-products of lipid
peroxidation (azelaic acid, malondialdehyde, acetylcholine,
and S-farnesyl-L-cysteine), andN-oxidemodified amino acid
in 14 CFS/MEpatients and 11 controls. Results indicatedmean
IgMserum levels directed against oleic, palmitic, andmyristic
acid, azelaic acid, S-farnesyl-L-cysteine, and the N-oxide
derivatives to be significantly greater in CFS/ME patients
when compared to controls. In addition, significant and
positive correlations were exhibited in the CFS/ME group for
serum IgM levels directed against fatty acidmalondialdehyde
and azelaic acid, N-oxide derivatives, and the severity of ill-
ness asmeasured by the fibro fatigue scale. Furthermore, pos-
itive correlations were also reported for the aforementioned
products and measures of muscle tension and fatigue. There-
fore, it would appear that autoimmune responses as a con-
sequence of oxidative damage to endogenous lipid epitopes
could play a pivotal role inCFS/ME associatedmuscle fatigue.
4. Mitochondrial Dysfunction
There is evidence to suggest that mitochondrial dysfunction
plays a key role in CFS/ME aetiology. Lowered ATP produc-
tion, impaired oxidative phosphorylation, andmitochondrial
damage have been reported in patients with CFS/ME [23, 24].
Moreover, CFS/ME patients share common skeletal muscle
symptoms associated with diseases linked to mitochondrial
dysfunction, for example, muscle pain, fatigue, and cramping
[61, 62].
There is accumulating evidence to suggest that abnor-
mally high lactate levels and intracellular acidosis exhibited
in patients with CFS/ME are the result of impaired mito-
chondrial function [61, 63]. For example, CFS/ME patients
exhibit profound and sustained intracellular acidosis of the
peripheral musculature following relatively low-level exer-
cise.This results in a decreased anaerobic threshold (AT) due
to an overutilisation of the lactate dehydrogenase pathway
[15, 41]. Upon the point of exhaustion CFS/ME patients have
been reported to exhibit intracellular ATP concentrations
that are lower than those found in nondiseased control
participants, which could be indicative of dysfunction in
oxidative metabolism. Moreover, in a recent review [61] the
authors concluded the response to exercise exhibited by
CFS/ME patients to be typical of that reported in individuals
with mitochondrial disease. Additionally, there were also
a number of similarities between symptoms of mitochon-
drial disease and the physiosomatic symptoms of CFS/ME.
For example, muscle pain, cramps, weakness, and myalgia’s
[54, 62, 64].
Mitochondrial dysfunction in CFS/MEmay be explained
by not only elevated oxidative and nitrosative stress but also
increased immune-inflammatory stress pathways [65]. Inter-
estingly, chronic low-grade inflammation in CFS/ME has
been demonstrated through increased levels of proinflam-
matory cytokines (IL-1, TNF-𝛼) and a movement towards a
Th2 dependant immune response, in addition to inflamma-
tory mediators including NF-𝜅B and elastase [64]. Further
evidence of elevated oxidative and nitrosative stress has also
been demonstrated by increased isoprostane levels, perox-
ides, and protein carbonyl levels, indicating damage to lipids,
protein, and mT as previously discussed [22].
In relation to immune dysfunction, one study examined
cytokine networks in 40 female CFS/ME patients and 40
case matched controls [32]. The authors examined a total of
16 cytokines and results revealed a diminution of Th1 and
Th17 function and a movement towards Th2 type immunity.
Similarly, several other groups have reported a shift for a
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Th1 to Th2 cytokine profile in CFS/ME patients [33, 34, 66].
For example, Skowera and colleagues [34] examined the
frequency of type 1 and type 2 regulator CD4 and CD8 T cells
in 35 patients with CFS. Results illustrated a bias towards a
Th2 immune response.
Elevated levels of the inflammatory mediator NF-𝜅B [67,
68] have also been reported in CFS/ME. NF-𝜅B is a major
upstream intracellular mechanism, which regulates inflam-
matory and oxidative stress mediators [68]. For example, it
functions to trigger inducible nitric oxide synthetase (iNOS)
expression, which promotes the production of nitric oxide
(NO) by monocytes and macrophages [68].
Juel and colleagues [55, 56] examined the production of
NF-𝜅B P50 in unstimulated 10 ng/mL TNF-𝛼 and 50 ng/mL
PMA (phorbol 12-myristate 13-acetate, PMA) stimulated
peripheral blood lymphocytes in 18 CFS/ME patients and 18
age-matched controls. Results demonstrated both unstimu-
lated (10 ng/mL) TNF-𝛼 (𝑃 = 0.0009) and PMA (0.008)
stimulated production of NF-𝜅B to be significantly higher in
CFS/MEpatients compared to controls. Additionally, positive
correlations were reported between the production of NF-𝜅B
and severity of illness in CFS/ME patients (as measured by
fibro fatigue scale) and with symptoms, including muscular
fatigue and tension. The function of p53 is pivotal in the
regulation of glycolysis and mitochondrial respiration as it
reduces the activity of the glycolytic pathway and stimu-
lates mitochondrial O
2
consumption and aerobic respiration.
However, when inhibited there is a shift to anaerobic glycol-
ysis and reduced O
2
consumption [65].
Aside from immune dysfunction, several studies have
reported mitochondrial dysfunction to be caused by abnor-
mal levels of key mitochondrial enzymes. For example, in a
paper by Smits and colleagues [69] a significant reduction in
citrate synthase in biopsies (quadriceps region) from patients
with CFS/ME was reported when compared to healthy
control samples. Citrate synthase is an enzyme located in
the mitochondrial matrix, which plays a critical role in the
tricarboxylic cycle [70]. Similarly, the McArdle group [35]
reported a decrease in citrate synthase as well as succinate
reductase and cytochrome- C oxidase (Complex IV), which
are two of the four mitochondrial transmembrane enzyme
complexes of the electron transport chain. Nevertheless, in
contrast to theMcArdle group [35], Smits and colleagues [69]
attributed the decrease in transmembrane enzymes to be the
result of reduced physical activity levels, frequently present
in CFS/ME patients as opposed to underlying mitochondrial
dysfunction. Nonetheless, a paper by Edwards and colleagues
[36] reported there to be no significant difference in partial
cytochrome-C oxidase in skeletal muscle biopsies between
CFS/ME patients and healthy matched controls.
Evidence also exists to suggest that CFS/ME patients
exhibit significantly reduced levels of coenzyme Q10, an
importantmitochondrial nutrient that functions as a cofactor
for the production of ATP in the mitochondria and displays
significant antioxidant activity [71]. In a study conducted by
Maes and colleagues [37], CFS/ME patients (𝑛 = 58) dis-
played significantly lowered plasma coenzyme Q10 concen-
tration compared to healthy controls (𝑛 = 22). Moreover, in
CFS/ME patients there was a significant inverse relationship
exhibited between plasma coenzyme Q10 concentration and
fatigue severity measured by means of the fibro fatigue scale.
Furthermore, CFS/ME patients may also exhibit alter-
ations in L-carnitine and acylcarnitine homeostasis [72]. L-
carnitine is a ubiquitously occurring trimethylated amino
acid that plays an important role in the transport of long
chain fatty acids across the inner mitochondrial membrane,
which is essential for energy production via fatty acid
metabolism [72]. Previous studies have reported a reduction
in endogenous plasma L-carnitine and total carnitine levels
in patients with CFS/ME [73, 74]. Nevertheless, other studies
have not always replicated these findings [75, 76]. Reuter and
Evans [72] postulated this to be related to the use of varying
methodological approaches, with some studies solely focused
on free carnitine and total carnitine rather than the level of
each individual acylcarnitine, which may be “cancelled out”
by normal levels of other acylcarnitines in CFS/ME patients.
To overcome this weakness Reuter and Evans [72] utilised
tandem mass spectrometry to quantify individual acylcar-
nitine levels in plasma samples to provide a more detailed
carnitine profile. Results demonstrated significant alterations
in C8:1, C12DC, C14, C16:1, C18, C18:1, C18:2, and C18:1-Oh
acylcarnitines.What ismore, significant correlations between
acylcarnitine and clinical symptomology were observed.
5. Postexertional Malaise and
Immune Function
CFS/ME patients report a changeable pattern to their symp-
toms andphysical and cognitive capabilities, oftenwith severe
symptom exacerbation following physical exercise [10, 25].
This is termed PEM, with approximately 95% of CFS/ME
patients experiencing PEM [77]. As regards the cause of PEM,
it has been suggested that exercise may exhibit the ability
to amplify preexisting immune abnormalities, in addition to
oxidative and nitrosative stress [78]. Immunological abnor-
malities have been reported following exercise in CFS/ME.
For example, observations in CFS/ME symptom flare after
moderate intensity exercise have been reported to be directly
linked to the levels of interleukin-1𝛽 (IL-1𝛽), IL-12, IL-8,
IL-10, and IL-13, 8 hours after exercise [38]. Additionally,
sustained increase in plasma TNF-𝛼 in CFS/ME patients and
not in healthy controls has been observed after exercise [38].
Moderate intensity exercise has also been reported to induce
a larger 48-hour postexercise area under the curve for IL-10
[39].
However, a recent systematic review [40] compared 23
case control studies regarding exercise-induced immuno-
logical changes in CFS/ME patients versus healthy control
participants. The authors reported in comparison to healthy
participants that CFS/ME patients exhibited a more exagger-
ated response in the complement system, indicated by C4a
split product level and enhanced oxidative stress, combined
with a delayed and reduced antioxidant response. Finally, the
authors also reported there to be an apparent alteration in
immune cell gene expression profile, which was evidenced
by an increase in postexercise IL-10 and toll-like receptor 4
gene expression. Nonetheless, in contrast to previous work
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there was no reported change in circulating pro- and/or anti-
inflammatory cytokines. Effectively, the review confirmed
CFS/ME patients to respond differently to an exercise-based
stimulus, resulting in a more pronounced immune response.
6. Muscle Bioenergetic Dysfunction
Even a minimal decrease in muscle pH interferes with
cross bridge binding and ATPase activity due to competi-
tive binding and reduced enzyme function [71]. Decreased
intracellular pH impairs oxidative enzyme activity and may
adversely affect ryanodine receptor function [79]. Recent
studies have also confirmed the presence of a peripheral
bioenergetic abnormality in CFS/ME patients [15, 41, 63].
In a cross-sectional study conducted by Jones et al. [15]
novel MRS techniques were utilised to investigate muscle
acid handling following exercise in CFS/ME patients and the
relationship with autonomic dysfunction. CFS/ME patients
(𝑛 = 16) and age- and sex-matched normal controls (𝑛 =
8) performed an exercise protocol, which consisted of 3
minutes of plantar flexion at 35% load maximum voluntary
contraction (MVC) at a rate of 0.5Hz, followed by 3-minute
recovery. After the period of exercise, phosphorus magnetic
resonance spectroscopy (PMRS) was utilised to investigate
intramuscular acid handling. Results demonstrated a signifi-
cant suppression of proton efflux immediately after exercise
(𝑃 < 0.05) in CFS/ME patients and significantly (𝑃 <
0.05) prolonged time taken to reach maximum proton efflux.
In controls, a strong inverse correlation between maximum
proton efflux and nadir pH following exercise (𝑟2 = 0.6,
𝑃 < 0.01) was reported.However, in CFS/ME the significance
of this relationship was lost (𝑟2 = 0.003; 𝑃 = ns). Collectively,
these findings demonstrated CFS/ME patients to exhibit
abnormalities in the recovery of intramuscular pH following
standardised exercise. Effectively, proton efflux is crucial
for acidosis resolution, with the immediate postexercise
period associated with maximum proton efflux in healthy
individuals; however this initial fast phase does not appear to
occur in all CFS/ME patients [15]. Furthermore, the authors
also acknowledged there to be a close relationship between
the degree of intramuscular acidosis and proton efflux,
demonstrating a closely regulated process, which has been
observed in healthy individuals [80] in addition to the study
control group. Nevertheless, they concluded this relationship
to be lost in CFS/ME patients. However, the relatively small
sample size of this study made it difficult to draw firm
conclusions. Therefore, further adequately powered studies
are required to investigate the relationship further.
In contrast, Wong et al. [42] reported no difference
in intramuscular pH at rest and exhaustion and during
early and late recovery, following a graded exercise test to
exhaustion. Measurement of intramuscular pH of the gas-
trocnemius muscle was performed via 31P nuclear magnetic
resonance (NMR) spectroscopy. However, the authors did
report changes in PCr and pH to occur more rapidly at the
onset of exercise in CFS/ME patients compared to controls,
which was suggested to be indicative of accelerated glycolysis.
Nevertheless, the authors postulated this finding to reflect
a lower level of physical endurance due to inactivity in
the CFS/ME patient cohort. Nonetheless, it is important to
interpret this study with caution, as the CFS/ME patients
were able to complete a maximal exercise test to exhaustion.
Therefore, it suggests that the patients in this study were not
severely incapacitated by the condition and thereforemay not
be representative of the wider CFS/ME population.
Alternatively, Jones et al. [41] reported prolonged postex-
ercise recovery from acidosis. In this investigation CFS/ME
patients and age/sex-matched healthy controls performed a
similar exercise protocol (35% MVC plantar flexion for 180 s
and 390 s recovery, repeated 3 times). In addition, partici-
pants were also required to perform a MVC assessment and
a cycle based cardiorespiratory fitness test. Results revealed
the ability to divide patients into two distinct groups; 8 (45%)
demonstrated normal phosphocreatine (PCr) depletion in
response to exercise at 35%MVC, with MVC strength values
comparable to controls. In the second grouping, 10 CFS/ME
patients exhibited low PCr depletion (generating abnormally
low MVC values). Results demonstrated anaerobic threshold
(AT), VO
2
, and VO
2
peak to be significantly reduced in
all CFS/ME patients compared to controls. Essentially, one
implication of a reduced AT would be a reliance upon anaer-
obic as opposed to aerobic metabolism, with the predicted
consequence of greater short-term acid generation within
the muscle as a result of an overutilisation of the lactate
dehydrogenase pathway [15]. This was further confirmed by
MRS demonstrating CFS/ME patients to exhibit markedly
increased intramuscular acidosis compared to controls at a
similar work rate following each 3-minute bout, with prolon-
gation (almost 4-fold) in the time taken for pH to recover to
baseline, replicating previous findings [15].
Based on the findings the authors suggested that the pro-
found intramuscular acidosis exhibited with repeat exercise
to be at least in part related to poor aerobic capacity. This
in relation to the physiology of fatigue closely mirrors that
observed in patients with the autoimmune disease primary
biliary cirrhosis (PBC). PBC exhibits a comparable peripheral
pattern and a similar level to fatigue to CFS/ME [81]. In
a study by Hollingsworth and colleagues [81] PBC patients
exhibited profound and comparable intramuscular acidosis
to the CFS/ME patients in the Luin et al. study [53] following
the same repeat exercise protocol. However, one pivotal
difference between the conditions, which may contribute to
the severity of fatigue in CFS/ME, relates to acid homeostasis.
In contrast to CFS/ME patients, when PBC patients undergo
repeat exercise the extent of acidosis within the muscle
decreases with each repeated exercise bout. This may suggest
a compensatorymechanism, which operates to resolve excess
acidosis. One potential mechanism that may account for this
is increased proton flux and the speed of onset of maximum
proton excretion with repeat exercise [41, 81]. This mech-
anism also plays a role in mitochondrial disease whereby
increased proton efflux postexercise helps to compensate for
decreased aerobic capacity [82].Nevertheless, it would appear
that in comparison to other conditions that exhibit reduced
aerobic capacity and acidosis, CFS/ME patients are unable to
compensate for an increased reliance upon anaerobic energy
pathways during exercise [41].
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While the production of protons as a by-product of
anaerobic metabolism is a feature of normal metabolism, the
body requires mechanisms to effectively manage protons as
even small changes in pH dramatically alter enzyme kinetics,
decrease muscle function, and cause fatigue [83]. Thus, slow
recovery from acidosis in CFS/ME may relate to the ineffec-
tive exporting of protons from the recoveringmuscle. Protons
are actively transported out of the muscle by 3 main groups
of proton transporters [55, 56]: Na+/H+ antiporters, namely,
NHE1 [84], sodium/bicarbonate cotransporters (NBCs) [85],
and most predominantly monocarboxylate transporters
(MCT), whereby in the latter group MCT-1 and MCT-4
isoforms seem to be of particular importance in human
skeletal muscle [86]. During rest, intramuscular pH is pri-
marily influenced by NHEs, with MCTs and NBCs playing a
greater role during the recovery from muscular contraction.
These transporter systems are under autonomic regulation
[87]. It is possible that the impaired function of acid trans-
porters occurs in CFS/ME, which may be a consequence
of autonomic dysfunction [88–90]. Additionally, it is also
possible that reduced vascular runs off (related to autonomic
dysfunction), resulting in decreased vascular flow into and
out of the muscle following exercise whichmay have an effect
on O
2
delivery, potentially limiting the function of the three-
enzyme complex pyruvate dehydrogenase complex (PDC)
[91].
A subgroup of patients (low PCr depletion) exhibited
no excess acidosis, which appeared to be entirely the conse-
quence of lowerMVC values compared to normal PCr deple-
tion controls. Interestingly, despite markedly lower MVC
values the patients perceived themselves to be working maxi-
mally immediately following the MVC assessment. However,
despite this perception the authors postulated that these
findings related to a type of exercise avoidance behaviour.
Kinesiophobia is defined as an excessive, irrational, and
debilitating fear of movement and activity resulting from a
fear of vulnerability to painful injury or reinjury [64, 71] and
has been reported to play a role in a variety of musculoskele-
tal disorders including CFS/ME patients who experience
widespread pain [92, 93]. Therefore, the fear of the conse-
quence of an action such as exercise may lead to avoidance
behaviour in patients with CFS/ME patients [41]. However,
the study was limited, as it did not include a repeat assess-
ment.
Interestingly, previous studies have also reported the exis-
tence of subgroupswithinCFS/MEpatient cohorts in relation
to glycolytic metabolism and intramuscular pH regulation
[18, 20, 42, 43]. However, unlike the studies conducted by
Jones et al. [15, 41], the earlier studies have reported an
absence in abnormal glycolytic metabolism in the majority
of the CFS/ME patients. Barnes et al. [18] explored intra-
muscular pH regulation in 46 CFS/ME patients via 31P MRS.
Results demonstrated no consistent abnormalities in glycol-
ysis or pH regulation at rest or following exercise when the
group was taken as a whole. Nonetheless, 12 patients did
exhibit abnormal PCr depletion following exercise, with 6
patients within this group displaying increased intramuscular
acidification in relation to PCr depletion and the other 6
demonstrating reduced acidification. This study illustrates
the heterogeneity within the CFS/ME patient population
and suggests that subgroups do exist in CFS/ME that dis-
play abnormal glycolytic metabolism and intramuscular pH.
Similarly, in Lane et al.’s studies [20, 43] CFS/ME patients
completed a subanerobic threshold exercise protocol. Results
revealed only a small subgroup (8%) of CFS/ME patients to
have an increased blood lactate response to exercise andmus-
cle biopsies revealed a relative increase in type 2 glycolytic
fibres for this subgroup.
7. Acidosis because of Impaired PDC Function
It is possible that the previously demonstrated muscle cell
acidosis in CFS/ME is the consequence of downregulated
PDC function and a concomitant increase in the metabolism
of pyruvate to lactic acid (overutilisation of lactate dehy-
drogenase (LDH) pathway). PDC is a 3-protein complex
responsible for a series of reactions that convert pyruvate to
acetyl coA during aerobic respiration. Principally, when the
function of this complex is reduced, pyruvate that has been
generated by glycolysis accumulates within the cells and is
metabolised anaerobically to lactic acid. This accumulation
causes a drop in pH and concurrent deterioration in muscle
function [94].
The phenotype of fatigue exhibited by CFS/ME patients
closely mirrors that seen in fatigue associated primary biliary
cirrhosis patients (PBC). For example, Hollingsworth et al.
[81] reported PBC patients to exhibit significant acidosis due
to an overutilisation of the lactate dehydrogenase pathway,
following a low-level repeat exercise protocol [81]. Further-
more, the authors postulated that the increased dependence
on anaerobic pathways of energy production resulted in
the fatigue associated with PDC. The idea that impaired
PDC function leads to an overutilisation of the lactate
dehydrogenase pathway is in agreement with other studies.
For example, Murrough et al. [95] reported significantly
higher levels of lactate in ventricular cerebrospinal fluid
in CFS/ME patients when compared to healthy controls.
Similarly, Constantin-Teodosiu and colleagues [96] in an
experimental exercise model using rats demonstrated that
when PDC function was decreased via the use of PPAR
modulating drugs which upregulated PDK function, lactate
accumulated intramuscularly which led to decreased muscle
function.
Therefore, impaired energy generation in muscle, an
increase in the lactate/pyruvate ratio in CFS/MEpatients, and
a propensity towards excess intramuscular acidosis following
limited exercise suggest PDC dysfunction in the muscle of
CFS/ME patients, which has implications in relation to the
expression of fatigue. Furthermore, as previously discussed
CFS/ME patients display significant intramuscular abnor-
malities relating to both acid generation and clearance from
tissue, which has been postulated to relate to a centrally per-
ceived “stop signal,” leading to a disproportionate perception
of fatigue [71].
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8. Abnormal AMPK Activation and
Glucose Uptake
A recent study [26] reported striking biochemical differences
in skeletal muscle cultures established from 10 CFS/ME
patients and 7 age-matched controls. Samples were subjected
to electrical pulse stimulation (EPS), for 24 hours, and
examined for exercise-associated changes. Key differences
emerged, in the basal state; there was increased myogenin
expression in CFS/ME samples but a decrease in IL-6
secretion during differentiation when compared to control
samples. Following 16 hours of EPS there was a significant
increase (𝑃 < 0.006) in AMP-activated protein kinase
(AMPK) phosphorylation and glucose uptake (𝑃 < 0.0001)
in control samples when compared to unstimulated control
cultures. Alternatively, CFS/ME samples demonstrated no
increase in AMPK phosphorylation or glucose uptake. Nev-
ertheless, glucose uptake remained responsive to insulin, sug-
gesting exercise related dysfunction. Furthermore, IL-6 secre-
tion in response to EPS was significantly reduced (𝑃 < 0.05
versus corresponding control) across all time points mea-
sured.
As regards the function of AMPK, it is a phyloge-
netically conserved fuel-sensing enzyme, consisting of a
heterotrimeric complex composed of a catalytic 𝛼 subunit
and regulatory 𝛽 and 𝛾 subunits [97]. During exercise under
normal physiological conditions, AMPK is activated in the
skeletal muscle of healthy humans, with exercise suggested to
be the most powerful physiological activator of AMPK [98,
99]. Upon activation AMPK sets into motion processes that
increase ATP production, such as glucose transport and fatty
acid oxidation [97], while decreasing others that consume
ATP, for example, lipid and protein synthesis and cell growth
and proliferation [97, 99, 100]. Evidence also suggests AMPK
to have a broader range of actions including mitochondrial
biogenesis [99, 101] and skeletal muscle angiogenesis [102],
suggesting AMPK activation to play a key role in peripheral
muscle function during exercise.
However, it is important to consider the role of physical
activity on AMPK activation. For example, trained subjects
have been reported to express higher levels of 𝛼1 AMPK
in comparison to untrained individuals [103]. Furthermore,
a 3-week endurance training intervention with young male
participants resulted in increases in 𝛼1 and 𝛼2 AMPK protein
expression in addition to ACC-𝛽 phosphorylation, which
suggested basal activity of AMPK to be increased [104].
Therefore, it should be considered that the decreased
AMPK activation reported in CFS/ME muscle samples after
EPS might be the result of lowered physical activity levels
of the CFS/ME sample donors, when compared to control
donors. As regards study recruitment criteria, although par-
ticipants were age-matched, it was not specified whether any
measures had been taken to ensure donors were matched in
terms of physical activity habits. Future work is required with
patients and controls that are matched in terms of physical
activity.
In addition to impaired activation of AMPK, the study
also reported reduced IL-6 secretion in response to EPS.
Interestingly, previous studies have reported IL-6 to activate
AMPK in skeletal muscle by increasing the concentration of
cAMP and secondly by increasing the AMP :ATP ratio [105].
The inability of CFS/ME muscle cells to activate AMPK
and glucose uptake in addition to reduced IL-6 secretion in
response to EPS is suggestive of underlying peripheralmuscle
dysfunction inCFS/ME.However, further work is required to
investigate themechanisms that lead to impaired activation of
AMPK in those with CFS/ME.
9. Conclusion
CFS/ME patient perceptions of the nature of their condition
frequently cite “peripheral” as opposed to a central origin,
with many descriptions of their fatigue regularly referring to
difficulty inmaintainingmuscle activity due to perceived lack
of energy, or throughmuscle fatigue [15, 17].There is increas-
ing evidence to suggest thatmuscular biochemical abnormal-
ity may play a major role in CFS/ME associated fatigue. The
literature suggests patients to exhibit profound intramuscular
dysfunction regarding acid generation and clearance, with a
tendency towards an overutilisation of the lactate dehydroge-
nase pathway following relatively low-level activity. However,
the precisemechanisms underlying the dysfunction are yet to
be fully elucidated. There is a real need for adequately pow-
ered studies to examine PDC function in vitro, to determine
themechanisms responsible for bioenergetic dysfunction and
peripheral fatigue.
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